|
2024 Journal Article The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescenceAtkinson, Caroline, McInerney-Leo, Aideen, Proctor, Martina, Lanagan, Catherine, Stevenson, Alexander, Dehkhoda, Farhad, Caole, Mary, Maas, Ellie, Ainger, Stephen, Pritchard, Antonia, Johansson, Peter, Leo, Paul, Hayward, Nicholas, Sturm, Richard, Duncan, Emma and Gabrielli, Brian (2024). The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence. International Journal of Molecular Sciences, 25 (3) 1664, 1-12. doi: 10.3390/ijms25031664 |
|
2023 Journal Article Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradationChhabra, Yash, Seiffert, Pernille, Gormal, Rachel S., Vullings, Manon, Lee, Christine Mei Mei, Wallis, Tristan P., Dehkhoda, Farhad, Indrakumar, Sowmya, Jacobsen, Nina L., Lindorff-Larsen, Kresten, Durisic, Nela, Waters, Michael J., Meunier, Frederic A., Kragelund, Birthe B. and Brooks, Andrew J. (2023). Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation. Cell Reports, 42 (5) 112490, 112490. doi: 10.1016/j.celrep.2023.112490 |
|
2023 Journal Article The SOCS1 KIR and SH2 domain are both required for suppression of cytokine signaling in vivoDoggett, Karen, Keating, Narelle, Dehkhoda, Farhad, Bidgood, Grace M., Meza Guzman, Lizeth G., Leong, Evelyn, Kueh, Andrew, Nicola, Nicos A., Kershaw, Nadia J., Babon, Jeffrey J., Alexander, Warren S. and Nicholson, Sandra E. (2023). The SOCS1 KIR and SH2 domain are both required for suppression of cytokine signaling in vivo. Cytokine, 165 156167, 1-8. doi: 10.1016/j.cyto.2023.156167 |
|
2022 Journal Article Optimization of phosphotyrosine peptides that target the SH2 domain of SOCS1 and block substrate ubiquitinationChen, Hao, Wu, Yuntong, Li, Kunlun, Currie, Iain, Keating, Narelle, Dehkhoda, Farhad, Grohmann, Christoph, Babon, Jeffrey J., Nicholson, Sandra E. and Sleebs, Brad E. (2022). Optimization of phosphotyrosine peptides that target the SH2 domain of SOCS1 and block substrate ubiquitination. ACS Chemical Biology, 17 (2), 449-462. doi: 10.1021/acschembio.1c00884 |
|
2021 Journal Article Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligandsLinossi, Edmond M., Li, Kunlun, Veggiani, Gianluca, Tan, Cyrus, Dehkhoda, Farhad, Hockings, Colin, Calleja, Dale J., Keating, Narelle, Feltham, Rebecca, Brooks, Andrew J., Li, Shawn S., Sidhu, Sachdev S., Babon, Jeffrey J., Kershaw, Nadia J. and Nicholson, Sandra E. (2021). Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands. Nature Communications, 12 (1) 7032, 7032. doi: 10.1038/s41467-021-26983-5 |
|
2018 Journal Article The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspectsDehkhoda, Farhad , Lee, Christine M. M. , Medina, Johan and Brooks, Andrew J. (2018). The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Frontiers in Endocrinology, 9 (35) 35, 35. doi: 10.3389/fendo.2018.00035 |
|
2013 Journal Article The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitorsByron, Sara A., Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael G., Dehkhoda, Farhad, Blais, Steven P., Neubert, Thomas A., Mohammadi, Moosa and Pollock, Pamela M. (2013). The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. NeoPlasia, 15 (8), 975-988. doi: 10.1593/neo.121106 |
